Arizona Tribune - Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN

https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Regeneron Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT'S NEXT? If you suffered a loss in Regeneron stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire

Ch.Campbell--AT